Gefitinib (an EGFR Tyrosine Kinase Inhibitor) Plus Anlotinib (an Multikinase Inhibitor) for Untreated, EGFR-mutated, Advanced Non-Small Cell Lung Cancer (FL-ALTER): a Multicenter Phase III Trial.

Hua-Qiang Zhou,Ya-Xiong Zhang,Gang Chen,Qi-Tao Yu,Hua Zhang, Wu,Di Wu,Ying-Cheng Lin,Jun-Fei Zhu,Jian-Hua Chen, Xiao-Hua Hu,Bin Lan, Ze-Qiang Zhou,Hai-Feng Lin, Zi-Bing Wang,Xiao-Lin Lei, Suo-Ming Pan, Li-Ming Chen,Jian Zhang,Tian-Dong Kong,Ji-Cheng Yao, Xin Zheng, Feng Li,Li Zhang,Wen-Feng Fang

SIGNAL TRANSDUCTION AND TARGETED THERAPY（2024）

引用 0|浏览8

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要